Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: A review of the literature

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 9, 2004, Pages 497-513

  Qin, Lun Xiu ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; Metastasis; Molecular marker; Recurrence

Indexed keywords

BIOLOGICAL MARKER; CATENIN; CD44V ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; KALININ; MATRIX METALLOPROTEINASE; MELANOMA ANTIGEN; OSTEOPONTIN; TELOMERASE; TUMOR ANTIGEN; UVOMORULIN; VASCULOTROPIN;

CANCER DIAGNOSIS; CANCER RECURRENCE; CELL CYCLE; CELL PROLIFERATION; DISEASE MARKER; ENZYME ACTIVITY; HUMAN; LIVER CELL CARCINOMA; METASTASIS; PHENOTYPE; PLOIDY; PREDICTION; PRIORITY JOURNAL; REVIEW;

EID: 4344590372     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0572-9     Document Type: Review

References (238)

1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513-521
2. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M (2002) Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359:131-132
3. Ajiki T, Kamigaki T, Hasegawa Y, Fujino Y, Suzuki Y, Takeyama Y, Ku Y, Kuroda Y (2001) Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. Hepatogastroenterology 48:1266-1270
4. Amornmarn R, Bui MM, Prempree TB, Masood S (2000) Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy. Ann Clin Lab Sci 30:33-40
5. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Takada A, Fukumori K, Yano Y, Sumie S, Okuda K, Kumashiro R, Sata M (2003) Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumour markers and imaging studies. Eur J Gastroenterol Hepatol 15:641-648
6. Anker P, Stroun M (2000) Circulating DNA in plasma or serum. Medicina (B Aires) 60:699-702
7. Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S (2003) Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Br J Cancer 88:726-732
8. Asayama Y, Taguchi Ki K, Aishima Si S, Nishi H, Masuda K, Tsuneyoshi M (2002) The mode of tumour progression in combined hepatocellular carcinoma and holangiocarcinoma: an immunohistochemical analysis of E-CD, alpha-catenin and beta-catenin. Liver 22:43-50
9. Asgeirsson KS, Jmarkonasson JG, Tryggvadottir L, Olafsdottir K, Sigurgeirsdottir JR, Ingvarsson S, Ogmundsdottir HM (2000) Altered expression of E-CD in breast cancer: patterns, mechanisms and clinical significance. Eur J Cancer 36:1098-1106
10. Bankfalvi A, Krassort M, Vegh A, Felszeghy E, Piffko J (2002) Deranged expression of the E-CD/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 31:450-457
11. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002) Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2:311-315
12. Bettuzzi S, Scaltriti M, Caporali A, Brausi M, D'Arca D, Astancolle S, Davalli P, Corti A (2003) Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res 63:3469-3472
13. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI (2001) Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 44:523-533
14. Bisgaard ML, Jager AC, Dalgaard P, Sondergaard JO, Rehfeld JF, Nielsen FC (2001) Allelic loss of chromosome 2p21-16.3 is associated with reduced survival in sporadic colorectal cancer. Scand J Gastroenterol 36:405-409
15. Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS (2000) A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 89:32-38
16. Bohm JP, Niskanen LK, Pirinen RT, Kiraly K, Kellokoski JK, Moisio KI, Eskelinen MJ, Tulla HE, Hollmen S, Alhava EM, Kosma VM (2000) Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. J Pathol 192:321-327
17. Borstnar S, Vrhovec I, Svetic B, Cufer T (2002) Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin Breast Cancer 3:138-146
18. Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830
19. Buccoliero AM, Caldarella A, Arganini L, Mennonna P, Ammanati F, Taddei A, Taddei GL (2003) Oligodendroglioma: CD44 as a possible prognostic opportunity. Clin Neuropathol 22:169-175
20. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, Bundred NJ (2000) Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92:1329-1336
21. Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, Yoshida T, Yada I (2002) Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 8:1152-1156
22. Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G (2003) Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20:437-444
23. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10:355-362
24. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW (2000) Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231:552-558
25. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IO, So S, Fan ST (2002) Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 62:4711-4721
26. Chow V, Yuen AP, Lam KY, Tsao GS, Ho WK, Wei WI (2001) A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 127:59-63
27. Chung TW, Moon SK, Lee YC, Kim JG, Ko JH, Kim CH (2002) Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch Biochem Biophys 408:147-154
28. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535
29. Cui J, Zhou XD, Liu YK, Tang ZY, Zile MH (2001) Abnormal Cu-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China. World J Gastroenterol 7:542-546
30. Dazzi C, Cariello A, Maioli P, Magi S, Rosti G, Giovanis P, Giovannini G, Lanzanova G, Marangolo M (2003) A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. Cancer Invest 21:208-216
31. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M (2000) Prognostic impact of p53 status in Ewing sarcoma. Cancer 89:783-792
32. De Iorio P, Midulla C, Pisani T, Valli C, Grillo L, Di Cocco B, Nofroni I, Vecchione A (2001) Implication of laminin and collagen type IV expression in the progression of breast carcinoma. Anticancer Res 21:1395-1399
33. DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, O'Farrell AM, Cherrington JM (2003) Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 3:3
34. Diez M, Medrano M, Muguerza JM, Ramos P, Hernandez P, Villeta R, Martin A, Noguerales F, Ruiz A, Granell J (2000) Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res 20:3907-3912
35. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC (2003) From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics [Epub ahead of print]
36. Emi Y, Kitamura K, Shikada Y, Kakeji Y, Takahashi I, Tsutsui S (2002) Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 131:S217-221
37. Endo K, Terada T (2000) Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32:78-84
38. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A (2002) Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. Int J Gynecol Cancer 12:286-289
39. Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano G (2000) p53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol 11:393-397
40. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF (2000) Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 6:3966-3972
41. Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L (2000) p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 164:1177-1182
42. Fox SB, Taylor M, Grondahl-Hansen J, Kakolyris S, Gatter KC, Harris AL (2001) Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 195:236-243
43. Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y, Tagawa Y, Ayabe H (2000) Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 27:19-26
44. Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621-632
45. Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, Nakao T, Isobe N, Murata T, Takahashi C, Noda M, Imamura M (2001) RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing-cysteine-rich protein with Kazal motifs. Hepatology 33:189-195
46. Gadducci A, Cianci C, Cosio S, Carnino F, Fanucchi A, Buttitta F, Conte PF, Genazzani AR (2000) p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res 20:4793-4799
47. Gallego MG, Acenero MJ, Ortega S, Delgado AA, Cantero JL (2000) Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Colon Rectum 43:971-975
48. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. The Oncologist [Suppl 1], 37-44
49. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147-3152
50. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA (2001) Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57:675-679
51. Giannelli G, Antonaci S (2000) Biological and clinical relevance of Laminin-5 in cancer. Clin Exp Metastasis 18:439-443
52. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S (2002) Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 97:425-431
53. Giannelli G, Fransvea E, Bergamini C, Marinosci F, Antonaci S (2003) Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 9:3684-3691
54. Gilcrease MZ, Guzman-Paz M, Niehans G, Cherwitz D, McCarthy JB, Albores-Saavedra J (1999) Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86:2320-2326
55. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S (2002) Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52:19-24
56. Graflund M, Sorbe B, Karlsson M (2002) MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. Int J Oncol 20:1041-1047
57. Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V, Tindiliere F, Laurent A, Bellin MF, Bismuth H, Debuire B, Lemoine A (2003) Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg 238:241-248
58. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S (2001) Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol 165:1769-1772
59. Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Miyata A, Shimizu H, Satomura S (1999) Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 94:3028-3033
60. He P, Tang ZY, Ye SL, Liu BB (1999) Relationship between expression of α-fetoprotein messenger RNA and some clinical parameters of human hepatocellular carcinoma. World J Gastroenterol 5:111-115
61. Heinze T, Jonas S, Karsten A, Neuhaus P (1999) Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 19:2501-2503
62. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, Nakamura Y (2001) Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7:876-882
63. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95:506-512
64. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY (2000) Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 157:763-770
65. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT (2003) Gene expression predictors of breast cancer outcomes. Lancet 361:1590-1596
66. Huang GT, Lee HS, Chen CH, Sheu JC, Chiou LL, Chen DS (1999) Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma. Hepatogastroenterology 46:1923-1927
67. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S, Hamamoto Y (2002) Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62:3939-3944
68. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M (2002) alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 35:853-860
69. Ikeguchi M, Taniguchi T, Makino M, Kaibara N (2000) Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastroenterol 35:839-846
70. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi F, Fukao K (2002) Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 8:450-456
71. Ireland AP, Shibata DK, Chandrasoma P, Lord RV, Peters JH, DeMeester TR (2000) Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 231:179-187
72. Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T (2003) A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 22:461-470
73. Itano O, Ueda M, Kikuchi K, Shimazu M, Kitagawa Y, Aiura K, Kitajima M (2000) A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA. Oncogene 19:1676-1683
74. Itoh T, Shiro T, Seki T, Nakagawa T, Wakabayashi M, Inoue K, Okamura A (2000a) Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med 6:137-142
75. Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, Itoh H (2000b) Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 15:422-430
76. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M (1999) Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30:90-99
77. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N (2000a) Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59:68-74
78. Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H, Nakamori S, Dono K, Sakon M, Nakamura M, Tsujimoto M, Nakahara M, Nakao K, Yokosaki Y, Matsuura N (2000b) The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 82:1211-1217
79. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N (2001) Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 84:1377-1383
80. Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617-623
81. Jeng KS, Sheen IS, Chen BF, Wu JY (2000) Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 135:1329-1333
82. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, Weber TK, Driscoll DL, Anderson GR, Petrelli NJ (2000) p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 88:1814-1819
83. Kantola S, Parikka M, Jokinen K, Hyrynkangs K, Soini Y, Alho OP, Salo T (2000) Prognostic factors in tongue cancer - relsative importance of demographic, clinical and histopathological factors. Br J Cancer 83:614-619
84. Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdaroglu F, Ozarmagan S (2002) Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest 25:578-585
85. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G (2002) Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236:37-42
86. Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y (1999) Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57:157-163
87. Kaye PV, Radebold K, Isaacs S, Dent DM (2000) Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol 26:39-43
88. Kennedy S (2001) Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett 120:379-384
89. Kienle P, Weitz J, Klaes R, Koch M, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M (2000) Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma. Arch Surg 135:213-218
90. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y (2003) Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anticancer drugs. Oncogene 22:2192-2205
91. King KL, Li AF, Chau GY, Chi CW, Wu CW, Huang CL, Lui WY (2000) Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 88:2464-2470
92. Kobayashi T, Kubota K, Takayama T, Makuuchi M (2001) Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 181:284-288
93. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M (1999) Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 5:4005-4012
94. Korn WM (2001) Moving toward an understanding of the metastatic process in hepatocellular carcinoma. World J Gastroenterol 7:777-778
95. Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, Shuto T, Yamamoto T, Kawai S, Wakasa K, Nishiguchi S, Kinoshita H (2002) Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg 26:555-560
96. Kuroi K, Toi M (2001) Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 16:5-26
97. Kuyvenhoven JP, Van Hoek B, Blom E, Van Duijn W, Hanemaaijer R, Verheijen JH, Lamers CB, Verspaget HW (2003) Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thromb Haemost 89:718-725
98. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, Mira E, Iniguez MA, Fresno M, Martinez AC, Arroyo AG, Lopez-Cabrera M (2002) The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 110:1831-1838
99. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67
100. Leibovich BC, Cheng L, Weaver AL, Myers RP, Bostwick DG (2000) Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol 163:1756-1760
101. Li D, Mallory T, Satomura S (2001) AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 313:15-19
102. Li XM, Tang ZY, Qin LX, Zhou J, Sun HC (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 18:511-517
103. Li Y, Li Y, Tang R, Xu H, Qiu M, Chen Q, Chen J, Fu Z, Ying K, Xie Y, Mao Y (2002) Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol 128:369-379
104. Lin JC, Chen KY, Wang WY, Jan JS, Liang WM, Wei YH (2002) Evaluation of cytokeratin-19 mRNA as a tumor marker in the peripheral blood of nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Cancer 97:548-553
105. Liu BB, Ye SL, He P, Liu YK, Tang ZY (1999) MAGE-1 and related MAGE gene expression may be associated with hepatocellular carcinoma. J Cancer Res Clin Oncol 125:685-689
106. Lohi J (2001) Laminin-5 in the progression of carcinomas. Int J Cancer 94:763-767
107. Loric S, Paradis V, Gala JL, Berteau P, Bedossa P, Benoit G, Eschwege P (2001) Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 37:1475-1481
108. Masaki T, Goto A, Sugiyama M, Matsuoka H, Abe N, Sakamoto A, Atomi Y (2001) Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer 92:2539-2546
109. Masaki T, Matsuoka H, Sugiyama M, Abe N, Izumisato Y, Sakamoto A, Atomi Y (2003) Laminin-5 gamma2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomas. Dig Dis Sci 48:272-278
110. Masuda M, Kuratomi Y, Shiratsuchi H, Nakashima T, Naonobu K, Komiyama S (2000) Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck 22:662-665
111. Matsumura M, Shiratori Y, Niwa Y, Tanaka T, Ogura K, Okudaira T, Imamura M, Okano K, Shiina S, Omata M (1999) Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma. J Hepatol 31:332-339
112. Matsumura T, Makino R, Mitamura K (2001) Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 7:594-599
113. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R (2003) Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63:1920-1926
114. Minata M, Nishida N, Komeda T, Azechi H, Katsuma H, Nishimura T, Kuno M, Ito T, Yamamoto Y, Ikai I, Yamaoka Y, Fukuda Y, Nakao K (2001) Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 16:445-451
115. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055-4063
116. Miyamoto A, Fujiwara Y, Sakon M, Nagano H, Sugita Y, Kondo M, Eguchi H, Dono K, Umeshita K, Nakamori S, Monden M (2000) Development of a multiple-marker RT-PCR assay for detection of micrometastases of hepatocellular carcinoma. Dig Dis Sci 45:1376-1382
117. Miyamoto A, Nagano H, Sakon M, Fujiwara Y, Sugita Y, Eguchi H, Kondo M, Arai I, Morimoto O, Dono K, Umeshita K, Nakamori S, Monden M (2001) Clinical application of quantitative analysis for detection of hematogenous spread of hepatocellular carcinoma by real-time PCR. Int J Oncol 18:527-532
118. Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farre G, Labib T, Pottier G, Sesboue R, Bronner C, Vignaud JM, Martinet Y, Martinet N (2000) Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 6:1125-1134
119. Morin PJ (1999) beta-catenin signaling and cancer. Bioessays 21:1021-1030
120. Morinaga S, Imada T, Shimizu A, Akaike M, Sugimasa Y, Takemiya S, Takanashi Y (2001) Angiogenesis in hepatocellular carcinoma as evaluated by alpha smooth muscle actin immunohistochemistry. Hepatogastroenterology 48:224-228
121. Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, Leng XS, Chen WF (2002) Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 86:110-116
122. Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y (2000) p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res 6:526-530
123. Murawaki Y, Ikuta Y, Okamoto K, Mimura K, Koda M, Kawasaki H (2000) Plasma matrix metalloproteinase-9 (gelatinase B) in patients with hepatocellular carcinoma. Res Commun Mol Pathol Pharmacol 108:351-357
124. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, Saku T, Takagi R (2003) Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 106:683-689
125. Nakajo A, Natsugoe S, Ishigami S, Matsumoto M, Nakashima S, Hokita S, Baba M, Takao S, Aikou T (2001) Detection and prediction of micrometastasis in the lymph nodes of patients with pN0 gastric cancer. Ann Surg Oncol 8:158-162
126. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838-845
127. Nieder C, Petersen S, Petersen C, Thames HD (2001) The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma. Ann Hematol 80:2-8
128. Nishida N, Fukuda Y, Komeda T, Ito T, Nishimura T, Minata M, Kuno M, Katsuma H, Ikai I, Yamaoka Y, Nakao K (2002) Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. Oncology 62:141-148
129. Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH (2000) Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 6:565-568
130. Niu Q, Tang ZY, Qin LX, Ma ZC, Zhang LH (2003) Loss of heterozygosity at D14S62 and D14S51 detected by a simple and non-radioactive method in plasma DNA is a potential marker of metastasis and recurrence after curative hepatic resection in hepatocellular carcinoma. Hepatogastroenterology 50:1579-1582
131. Nogi H, Takeyama H, Uchida K, Agata T, Horiguchi-Yamada J, Yamada H (2003) Detection of MUC1 and keratin 19 mRNAs in the bone marrow by quantitative RT-PCR predicts the risk of distant metastasis in breast cancer patients. Breast Cancer 10:74-81
132. Ntzani EE, Ioannidis JP (2003) Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362:1439-1444
133. Nunes DN, Kowalski LP, Simpson AJ (2001) Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas. Int J Cancer 92:214-219
134. Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N, Namba M (2001) Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res 21:657-662
135. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M (2001) Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 16:1378-1383
136. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61:2129-2137
137. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M (2002) Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 17:772-778
138. Okuda K, Tanaka M, Kanazawa N, Nagashima J, Satomura S, Kinoshita H, Eriguchi N, Aoyagi S, Kojiro M (1999) Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 14:265-271
139. Ondruschka C, Buhtz P, Motsch C, Freigang B, Schneider-Stock R, Roessner A, Boltze C (2002) Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell
140. Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa H (2000) Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. J Hepatol 33:247-253
141. Osaki T, Kimura T, Tatemoto Y, Dapeng L, Yoneda K, Yamamoto T (2000) Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. Oncology 59:36-43
142. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J (2000) Tp53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 39:327-333
143. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119-127
144. Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, Sotsiou F, Pintzas A (2000) Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 20:2009-2013
145. Parasole R, Izzo F, Perrone F, Pignata S, Galati MG, Leonardi E, Castiglione F, Orlando R, Castello G, Esposito G, Gallo C, Daniele B (2001) Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res 7:3504-3509
146. Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, Robertson JF (2001) E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 85:1958-1963
147. Patarroyo M, Tryggvason K, Virtanen I (2002) Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 12:197-207
148. Patel A, Straight AM, Mann H, Duffy E, Fenton C, Dinauer C, Tuttle RM, Francis GL (2002) Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest 25:403-408
149. Philipp-Staheli J, Payne SR, Kemp CJ (2001) p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264:148-168
150. Pirisi M, Toniutto P, Uzzau A, Fabris C, Avellini C, Scott C, Apollonio L, Beltrami CA, Bresadola F (2000) Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 89:297-302
151. Poon RT, Fan ST, Wong J (2001a) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207-1225
152. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J (2001b) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227-235
153. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775-1785
154. Poon TP, Lau PY, Cheung ST, Yu WC, Fan ST (2003) Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma. Cancer Res 63:3121-3126
155. Prange W, Schirmacher P (2001) Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas. Oncol Rep 8:727-730
156. Qin LX, Tang ZY (2002) The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 8:193-199
157. Qin LX, Tang ZY, Sham JST, Ma ZC, Ye SL, Zhou XD (1999) The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 59:5662-5665
158. Qin LX, Tang ZY, Ye SL, Liu YK, Ma ZC, Zhou XD, Wu ZQ, Lin ZY, Sun FX, Tian J, Guan XY, Pack SD, Zhuang ZP (2001) Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol 127:482-488
159. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Ji Y, Huang LW, Jia HL, Sun HC, Wang L (2002) p53 immunohistochemistry scoring is an independent prognostic marker of patient with hepatocellular carcinoma resection: a prospective study of 256 formalin-fixed paraffin-embedded tumor samples. World J Gastroenterol 8:459-463
160. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, Sutherland RL (2000) Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60:1585-1594
161. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54
162. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L (2003) Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106:745-751
163. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3:489-501
164. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J (2000) The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88:804-813
165. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661-668
166. Rodrigo JP, Dominguez F, Alvarez C, Manrique C, Herrero A, Suarez C (2002) Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer 38:1059-1064
167. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198-205
168. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427
169. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A (1999) Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 79:604-610
170. Sakamoto Y, Mafune K, Mori M, Shiraishi T, Imamura H, Mori M, Takayama T, Makuuchi M (2000) Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 17:237-243
171. Sasaki H, Yukiue H, Kobayashi Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y (2002) Elevated serum pro-MMP2 levels in patients with stage IV thymoma. Surg Today 32:482-486
172. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH (2001) Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 19:448-457
173. Schulze G (2003) HER-2/neu gene product in serum - an oncoprotein in the diagnosis and therapy of breast carcinoma. Anticancer Res 23:1007-1010
174. Shahin MS, Hughes JH, Sood AK, Buller RE (2000) The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89:2006-2017
175. Shao ZM, Wu J, Shen ZZ, Nguyen M (2001) p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 7:2222-2227
176. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM (2001) Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92:2985-2992
177. Sheen IS, Jeng KS, Wu JY (2003) Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 9:1202-1207
178. Shnayder Y, Kuriakose MA, Yee H, Chen FA, DeLacure MD, Xue XN, Jagirdar J (2001) Adhesion molecules as prognostic factors in nasopharyngeal carcinoma. Laryngoscope 111:1842-1846
179. Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K (2003) Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103:647-651
180. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareno E, Colas A, Espana P, Bonilla F (2002) Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 8:3761-3766
181. Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y (2000) Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 19:6317-6323
182. Sneath RJ, Mangham DC (2000) CD44 isoform expression in synovial sarcoma correlates with epitheliogenesis but not prognosis. Histopathology 37:166-174
183. Sokmen S, Lebe B, Sarioglu S, Fuzun M, Terzi C, Kupelioglu A, Ellidokuz H (2001) Prognostic value of CD44 expression in colorectal carcinomas. Anticancer Res 21:4121-4126
184. Stavropoulos NE, Filliadis I, Ioachim E, Michael M, Mermiga E, Hastazeris K, Nseyo UO (2001) CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors. Int Urol Nephrol 33:479-483
185. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW (1999) p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162:2040-2045
186. Sugio K, Kase S, Sakada T, Yamazaki K, Yamaguchi M, Ondo K, Yano T (2002) Micrometastasis in the bone marrow of patients with lung cancer associated with a reduced expression of E-cadherin and beta-catenin: risk assessment by immunohistochemistry. Surgery 131:S226-231
187. Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S (1999) The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today 29:849-855
188. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A (2002) Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441:345-349
189. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC (1999a) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 125:419-426
190. Sun JJ, Zhou XD, Liu YK, Tang ZY, Feng JX, Zhou G, Xue Q, Chen J (1999b) Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule-1. J Cancer Res Clin Oncol 125:28-34
191. Suzuki K, Tsujitani S, Konishi I, Yamaguchi Y, Hirooka Y, Kaibara N (1999) Expression of MAGE genes and survival in patients with hepatocellular carcinoma. Int J Oncol 15:1227-1232
192. Suzuki M, Ohwada M, Saga Y, Kohno T, Takei Y, Sato I (2001) Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance. Oncology 60:170-175
193. Suzuki T, Yano H, Nakashima Y, Nakashima O, Kojiro M (2002) Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol 17:994-1000
194. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS (2001) Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 61:5723-5726
195. Tada K, Shiraishi S, Kamiryo T, Nakamura H, Hirano H, Kuratsu J, Kochi M, Saya H, Ushio Y (2001) Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 95:651-659
196. Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T (2000) Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 89:92-99
197. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98:9754-9759
198. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, Ochiai T, Ochiai A (2002) Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 94:1894-1901
199. Takeda A, Shimada H, Nakajima K, Imaseki H, Suzuki T, Asano T, Ochiai T, Isono K (2001) Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur J Surg 167:50-53
200. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89:1270-1275
201. Tamas L, Kraxner H, Mechtler L, Repassy G, Ribari O, Hirschberg A, Szentkuti G, Jaray B, Szentirmay Z (2000) Prognostic significance of p53 histochemistry and DNA histogram parameters in head and neck malignancies. Anticancer Res 20:4031-4037
202. Tanaka M, Kitajima Y, Sato S, Miyazaki K (2003) Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy. Br J Surg 90:95-101
203. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y (2000) Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 31:302-308
204. Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CL (2000) Telomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol 15:1064-1070
205. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S (2000) u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 87:644-649
206. Theret N, Musso O, Turlin B, Lotrian D, Bioulac-Sage P, Campion JP, Boudjema K, Clement B (2001) Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34:82-88
207. Thomas GV, Schrage MI, Rosenfelt L, Kim JH, Salur G, deKernion JB, Dorey F, Said J, Reiter RE (2000) Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 164:1987-1991
208. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419-429
209. Uenishi T, Kubo S, Hirohashi K, Yamamoto T, Ogawa M, Tanaka H, Shuto T, Kinoshita H (2002) Expression of bile duct-type cytokeratin in hepatocellular carcinoma in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett 178:107-112
210. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, Nishiguchi S (2003a) Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer 88:1894-1899
211. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K (2003b) Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 94:851-857
212. van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
213. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
214. Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY (1999) Blood platelets and serum VEGF in cancer patients. Br J Cancer 79:370-373
215. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157-166
216. Vis (2000)
217. Washburn JG, Wojno KJ, Dey J, Powell IJ, Macoska JA (2000) 8pter-p23 deletion is associated with racial differences in prostate cancer outcome. Clin Cancer Res 6:4647-4652
218. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 100:3410-3415
219. Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlmann D, Tannapfel A, Wittekind C, Hauss J (2002) Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 131:34-43
220. Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, Brakenhoff R, Pantel K (2003) Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63:5679-5684
221. Wong CM, Fan ST, Ng IO (2001a) beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92:136-145
222. Wong IH, Lau WY, Leung T, Yeo W, Johnson PJ (1999) Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 5:4021-4027
223. Wong IH, Lau WY, Leung T, Johnson PJ (2000) Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring. Cancer Lett 156:141-149
224. Wong IH, Yeo W, Leung T, Lau WY, Johnson PJ (2001) Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett 167:183-191
225. Woodman (2000)
226. Wu CC, Ho WL, Chen JT, Tang JS, Yeh DC, P'eng FK (1999) Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg 86:1391-1396
227. Xu L, Hui LJ, Wang SH, Gong JL, Jin Y, Wang YP, Ji Y, Wu X, Han ZG, Hu GX (2001a) Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 61:3176-3181
228. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG (2001b) Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 98:15089-15094
229. Yamamoto H, Itoh F, Iku S, Hosokawa M, Imai K (2001) Expression of the gamma(2) chain of laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Clin Cancer Res 7:896-900
230. Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M, Aozasa K (2003) Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol 21:447-452
231. Yamamoto Y, Ikai I, Yamaoka Y, Fukuda Y, Nakao K (2001a) Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 16:445-451
232. Yamamoto Y, Sakamoto M, Fujii G, Kanetaka K, Asaka M, Hirohashi S (2001b) Cloning and characterization of a novel gene, DRH1, down-regulated in advanced human hepatocellular carcinoma. Clin Cancer Res 7:297-303
233. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen YD, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinoma using gene expression profiling and supervised machine learning. Nature Med 9:416-423
234. Yeatman TJ, Chambers AF (2003) Osteopontin and colon cancer progression. Clin Exp Metastasis 20:85-90
235. Yoshizaki T, Maruyama Y, Sato H, Furukawa M (2001) Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95:44-50
236. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906-1913
237. Zhang LH, Qin LX, Ma ZC, Ye SL, Liu YK, Ye QH, Wu X, Huang W, Tang ZY (2003) Allelic Imbalance regions on Chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol 129:279-286
238. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB (2000) Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126:641-646